Photo of Paul Beavis from petermac.org
Aug 25, 2024, 15:49
New strategies to enable CAR T cells to overcome the major hurdles in solid tumors – CRI
Cancer Research Institute (CRI) shared on LinkedIn:
“While CAR T cell therapy has made transformational progress for some hematological malignancies, it has yet to make a significant impact on solid tumors, CRI Lloyd J. Old STAR Dr. Paul Beavis of University of Melbourne, Peter MacCallum Cancer Centre explains. In 2025, Dr. Beavis will take his CAR T therapy to a phase 1 clinical trial.
“Our major focus is to devise new strategies to enable CAR T cells to overcome the major hurdles to success in solid tumors: failure to persist, tumor-induced immunosuppression, tumor-antigen heterogeneity, and the challenge of trafficking to a solid tumor site,” he describes. Read more.”
Source: CRI/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33
Dec 21, 2024, 13:20
Dec 21, 2024, 13:12